SAMiRNA program (Bioneer/Yuhan)

N/A

Report date: 2025/06/11 10:48:01
NME

Base Information

Drug NameSAMiRNA program (Bioneer/Yuhan)
Drug Alias NameSAMiRNA program (Bioneer)KDDF-201706-03KDDF-201312-11
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBioneer Corp
China Registration ClassN/A

Develop Information

Active CompaniesBioneer CorpYuhan Corp
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic Obstructive
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A